GLP-1 and Addiction (2026): What the Research Shows on Cravings, Alcohol and Substance Use | PlexusDx

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

One of the most surprising stories of the GLP-1 era started in patient conversations, not clinical trials. People prescribed semaglutide or tirzepatide for type 2 diabetes or chronic weight management began reporting that their interest in alcohol, cigarettes, and other compulsive behaviors faded alongside their hunger — “food noise” reduction with a working hypothesis attached: GLP-1 receptor agonists modulate dopamine signaling in the brain’s reward circuitry, the same circuitry that governs substance cravings. This article explains what the emerging research actually shows about GLP-1 medications and addiction, what it doesn’t show, and how to think about it if you’re already considering a PlexusDx protocol like Semaglutide Injection, Tirzepatide Injection, or the Microdose GLP-1 Protocol for an FDA-approved indication. Framing upfront: no GLP-1 is FDA-approved for any addiction indication, and nothing here is a recommendation to use one to treat alcohol use disorder, opioid use disorder, or any other substance or behavioral addiction.

Why researchers are paying attention

The conversation accelerated in March 2026 with a cohort study of more than 600,000 U.S. veterans with type 2 diabetes, published in The BMJ, comparing GLP-1 users to those on SGLT2 inhibitors over three years. Among veterans with pre-existing substance use disorders, GLP-1 users were associated with roughly 50% fewer substance-related deaths and 39% fewer overdoses. Earlier signals lined up: a Swedish nationwide analysis of 227,000 people, multiple U.S. cohort studies, a Phase 2 randomized controlled trial in JAMA Psychiatry showing semaglutide reduced alcohol craving and consumption versus placebo, and a 2024 Reddit analysis in which 71% of alcohol-mentioning posts described reduced cravings on GLP-1 therapy. These are associations and early-stage trial signals — a pattern, not proof of causation. But the consistency across substances and study designs is what put the topic on every addiction researcher’s desk.

The mechanism: dopamine, reward circuitry, and “drug noise”

GLP-1 receptors are expressed not only in the gut and pancreas but in brain regions governing reward and motivation — the ventral tegmental area, nucleus accumbens, and prefrontal cortex. Animal studies show GLP-1 activation in these regions dampens dopamine release in response to alcohol, nicotine, cocaine, and high-palatability food cues. The clinical translation in obesity patients is what people describe as “food noise” quieting. Researchers now hypothesize the same mechanism may explain reports of parallel “drug noise” quieting — less pull toward the next drink or cigarette. A plausible mechanism is not the same as a proven treatment, and the gap between the two is exactly where current research is working.

Are GLP-1 medications FDA-approved to treat addiction?

No. As of 2026, no GLP-1 receptor agonist is FDA-approved for any addiction indication — not alcohol use disorder, not opioid use disorder, not nicotine cessation, not behavioral addictions. Semaglutide (Ozempic, Wegovy, Rybelsus) is FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction. Tirzepatide (Mounjaro, Zepbound) is approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea in adults with obesity. Liraglutide (Victoza, Saxenda) is approved for type 2 diabetes and chronic weight management. Any use for an addiction indication is off-label. PlexusDx does not prescribe, recommend, or market any GLP-1 protocol for addiction — our Semaglutide Injection, Tirzepatide Injection, Microdose GLP-1 Protocol, GLP-Squared, Semaglutide Oral, and Tirzepatide Oral are dispensed for chronic weight management in eligible adults. If you have a substance use disorder, the starting point is a clinician-led conversation about FDA-approved addiction medications, not a GLP-1.

Substance-by-substance: what the human evidence currently shows

Alcohol use disorder — strongest signal. A randomized controlled trial in JAMA Psychiatry showed semaglutide reduced alcohol craving and consumption versus placebo over a nine-week treatment window. Multiple large observational studies show reduced AUD diagnosis rates and alcohol-related hospitalizations among GLP-1 users. Established AUD treatments — naltrexone, acamprosate, disulfiram, and structured behavioral therapy — have decades of evidence and remain the first-line standard of care.

Opioid use disorder — promising but preliminary. The BMJ veterans cohort showed reduced overdose risk and substance-related mortality. A small clinical study reported a roughly 40% reduction in opioid cravings. Multiple randomized trials are underway. Buprenorphine and methadone remain the evidence-based standard of care and should never be replaced without clinical guidance.

Nicotine and smoking — mixed. Some observational data and small trials show reduced cigarettes-per-day on GLP-1 therapy and the practical benefit of preventing post-cessation weight gain. Smoking-specific trial results have been inconsistent. Nicotine replacement therapy and varenicline have stronger cessation evidence.

Cocaine and stimulants — early. Observational signals exist; one small randomized trial was negative. No FDA-approved medication exists for cocaine use disorder.

Cannabis — weakest signal. One large observational analysis showed roughly a 14% reduced risk of cannabis use disorder — the smallest effect among substances studied. No clinical trials exist.

Behavioral addictions (gambling, shopping) — anecdotal only. Patient reports are accumulating and the mechanism is biologically plausible. No formal trials exist.

What this means if you’re already on a GLP-1 for an approved indication

Many patients on a GLP-1 for type 2 diabetes or chronic weight management notice secondary changes: less interest in alcohol, fewer late-night cravings, a quieter pull toward compulsive scrolling. That’s consistent with the dopamine-modulation literature, but it doesn’t mean the medication is “treating” an addiction the way naltrexone treats AUD or buprenorphine treats opioid use disorder. It also doesn’t mean the effect is permanent — long-term data on craving rebound after stopping a GLP-1 does not yet exist. Discuss any meaningful change in substance use with your clinician. If you’re considering a PlexusDx Semaglutide Injection or Tirzepatide Injection protocol for chronic weight management, the consultation, prescription, compounded medication, and shipping are bundled into one monthly price; secondary effects on cravings are individual and not guaranteed.

Why genetics shape your GLP-1 response

Independent of the addiction conversation, GLP-1 response varies across patients. Variants in GLP1R, GIPR, FTO, MC4R, and TCF7L2 are associated with differential weight-loss response, side-effect tolerability, and titration speed. The PlexusDx Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the headline GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician can anchor titration to a measurable baseline rather than population averages. The test is $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol. This isn’t a workaround for the absence of FDA approval for addiction; it’s about getting the dose right for the indication you do have.

Side effects, safety, and the boxed warning

Common GLP-1 side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, most pronounced during dose escalation. Less common but documented risks include pancreatitis, gallbladder disease, and acute kidney injury (often from dehydration). Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors based on rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN-2. GLP-1 medications themselves are not addictive, not controlled substances, and don’t produce withdrawal symptoms when stopped — though appetite, weight, and any secondary craving effects can rebound. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients, which is why PlexusDx uses licensed U.S. compounding pharmacies and a clinician-led titration pathway.

Cost, coverage, and the “is this for me” question

Insurance is unlikely to cover a GLP-1 for an addiction indication because none is approved for one. Coverage for type 2 diabetes is common; coverage for chronic weight management is inconsistent across commercial plans in 2026. PlexusDx Weight Management Protocols are cash-pay, no membership, available in all 50 states (five require a live consultation). Pricing: Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Semaglutide Oral from $249/mo, Tirzepatide Injection at $249/mo, Tirzepatide Oral at $279/mo, and GLP-Squared dual-compound at $249/mo. Each protocol bundles the async clinician consultation, prescription, compounded medication, and shipping into one monthly bill. None of these protocols are marketed for addiction.

If addiction is your primary concern, here’s what to do today

Start with an evidence-based addiction-specific resource, not a GLP-1. The SAMHSA National Helpline at 1-800-662-4357 is free, confidential, and available 24/7. FindTreatment.gov locates treatment near you. For crisis situations, call or text 988. For alcohol use disorder, ask a clinician about naltrexone, acamprosate, or disulfiram alongside structured counseling. For opioid use disorder, buprenorphine and methadone are the standard of care. The GLP-1-and-addiction research is moving fast — but acting on it ahead of FDA approval and clinician guidance trades a known intervention for an unknown one. If you have both an FDA-approved GLP-1 indication and a co-occurring substance use concern, that’s a conversation worth having with your prescribing clinician and an addiction specialist together.

Frequently asked questions

Are GLP-1 medications FDA-approved to treat addiction?

No. As of 2026, no GLP-1 receptor agonist is FDA-approved for alcohol use disorder, opioid use disorder, nicotine cessation, or any other addiction indication. Semaglutide and tirzepatide are approved for type 2 diabetes and chronic weight management. Any addiction-related use is off-label and not what PlexusDx prescribes for.

Does semaglutide reduce alcohol cravings?

A Phase 2 randomized trial in JAMA Psychiatry showed semaglutide reduced alcohol craving and consumption versus placebo, and large observational studies show similar associations. The signal is real but the medication is not approved for this use, and naltrexone or acamprosate remain the evidence-based first-line treatments for alcohol use disorder.

How could a GLP-1 affect substance cravings at all?

GLP-1 receptors are expressed in brain regions that govern reward and motivation, and animal studies show GLP-1 activation dampens dopamine release in response to addictive substances. This is the same mechanism patients describe as “food noise” quieting and may explain parallel reports of reduced “drug noise.” A plausible mechanism is not a proven treatment.

Are GLP-1 medications themselves addictive?

No. GLP-1 receptor agonists are not addictive, are not controlled substances, and do not produce withdrawal symptoms when stopped. Appetite, weight, and any secondary craving effects can rebound after discontinuation, which is a separate issue from physiologic dependence.

Can a GLP-1 replace naltrexone, buprenorphine, or methadone?

No. Established addiction medications have decades of evidence behind them and remain the standard of care. GLP-1s may eventually complement these treatments in research settings, but they are not a replacement today and should not be substituted without clinician guidance.

Does PlexusDx prescribe GLP-1 protocols for addiction?

No. PlexusDx Weight Management Protocols — including Semaglutide Injection at $179 to $229 per month, Tirzepatide Injection at $229 to $309 per month, and the $129 per month Microdose GLP-1 Protocol — are prescribed for chronic weight management in eligible adults. We do not market or prescribe any protocol for addiction.

What should I do if I’m already on a GLP-1 and noticed my cravings changed?

Tell your prescribing clinician. A measurable change in alcohol or substance use is worth documenting alongside your weight, blood pressure, and metabolic markers. If you have a substance use disorder, work with an addiction specialist on an evidence-based plan rather than relying on the GLP-1 alone.

Related reading on PlexusDx: GLP-1 Cost, Semaglutide Side Effects, Tirzepatide Side Effects, Cheapest GLP-1.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols for chronic weight management; no PlexusDx protocol is marketed, prescribed, or recommended for the treatment of addiction or any substance use disorder. Research described here on GLP-1 receptor agonists and substance cravings is early-stage and not the basis for an FDA-approved addiction indication. Pricing referenced for PlexusDx protocols reflects published rates as of April 2026; actual costs may vary by state and individual eligibility. Discuss any GLP-1 medication decision — and any addiction treatment decision — with a licensed clinician.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.